Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE PRESERVATIVE FREE versus MIVACRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE PRESERVATIVE FREE versus MIVACRON.
ATRACURIUM BESYLATE PRESERVATIVE FREE vs MIVACRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic cholinergic receptors at the neuromuscular junction, preventing depolarization and muscle contraction. Degraded via Hofmann elimination (non-enzymatic) and ester hydrolysis.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
0.4-0.5 mg/kg IV bolus for intubation; maintenance: 0.08-0.1 mg/kg IV every 15-25 min or continuous infusion 5-10 mcg/kg/min
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life of atracurium is approximately 20 minutes (range 15-35 min) in healthy adults; clinically, this short half-life correlates with rapid spontaneous recovery without the need for reversal agents, though prolonged in hypothermia or acidosis.
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Primarily via Hofmann elimination (non-enzymatic degradation) and ester hydrolysis; renal excretion accounts for less than 10% unchanged, with biliary/fecal elimination minimal. Approximately 40% as laudanosine and other metabolites via urine, with laudanosine further metabolized and renally excreted.
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker